ANYL 16 |
| Developing protein biomarkers for disease diagnostics involves two distinct stages – discovery and validation. Modern mass spectrometry is a key component of both stages, whether or not mass spectrometry ends up as the final diagnostic testing methodology. Accurate in depth descriptions of proteins in biological matrices is best obtained by differential analysis of peptides from multiple fast LC/MS/MS or MSn runs, especially where the MS data is collected in high resolution (10,000 – 100,000 FWHM) and accurate mass (<5ppm) mode. Key to the effective analysis of the large and complex data sets generated is software for routine differential analysis, reliable peptide (protein) identification, and accurate quantitation. The transition from discovery to validation requires a high throughput, yet precise, target peptide (protein) quantitation protocol. Such protocols can be developed on any tandem MS system such as the linear ion trap, but highly selective triple quadrupole selected reaction monitoring also holds promise. |
|
Disease Diagnostics
8:30 AM-10:55 AM, Sunday, 26 March 2006 Georgia World Congress Center -- B214, Oral
Division of Analytical Chemistry |